Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0605
E

Failure to Ensure Gradual Dose Reduction and Monitoring for Psychotropic Medications

Las Cruces, New Mexico Survey Completed on 11-18-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that residents did not receive unnecessary psychotropic medications and that adequate monitoring was in place for those receiving such medications. For one resident with diagnoses including dementia, insomnia, and major depressive disorder, there was no evidence of depressive symptoms since admission, as indicated by repeated PHQ-9 scores of zero. Despite this, the resident continued to receive escitalopram, oxcarbazepine, and trazodone at the same dosages without any documented attempt at gradual dose reduction (GDR) or clinical rationale for not attempting a GDR, even after a pharmacist recommended a dose reduction. The provider declined the recommendation without providing a clinical justification, and the medical record lacked documentation supporting the continued use of these medications at their current dosages. Additionally, the facility did not adequately monitor for adverse side effects or follow black box warning requirements for residents on antidepressant medications. Staff interviews revealed that nurses were not monitoring for suicidal thoughts, behaviors, or worsening depression symptoms, despite black box warnings attached to the orders for escitalopram and trazodone. Staff acknowledged these warnings in the electronic medical record but were not instructed on appropriate actions to take, and there was no documentation that providers were notified of the warnings or that residents were being monitored as required. A second resident with multiple psychiatric and neurocognitive diagnoses was prescribed duloxetine, which also carries a black box warning for monitoring suicidal thoughts and behaviors. However, there was no documentation in the medical record that this resident was being monitored for these symptoms. Nursing staff confirmed that unless the medication administration record (MAR) specifically instructed them to monitor for suicidal ideation, such monitoring and documentation did not occur. The DON confirmed the absence of monitoring and documentation for suicidal ideations, despite the presence of black box warnings and the expectation that staff would assess and communicate with providers as needed.

An unhandled error has occurred. Reload 🗙